Inhalation Sciences signs new partnership with Actarmo Medical: End-to-end offering for respiratory drug development Services

Inhalation Sciences AB (ISAB) has signed a new partnership with fellow European inhalation development service provider Actarmo Medical GmbH based in Germany. The new partnership is expected to enlarge the service scope and offerings to the client pipelines of both companies. ISAB and Actarmo have highly complementary services at either end of the respiratory drug development chain, in the fast-growing inhaled therapeutics market.

Inhalation Sciences AB has entered a new partnership with Actarmo Medical GmbH, a respiratory drug development services provider headquartered in Gauting, Germany. ISAB and Actarmo have complementary offerings that combined enable them to provide a more end-to-end services offering, from preclinical in vivo and in vitro pharmaco-kinetic studies to device testing and full development of inhalation combination products. This provides a vast competitive advantage for both companies and to their combined pipeline of inhalation clients. 

Successfully implementing ISAB’s Service Strategy

The new partnership supports and reinforces ISAB’s successful implementation of the strategic shift towards services as its main revenue stream delivered by its business area, Inhalation Research Services, to be able to better serve pharmaceutical- and medical device customers within inhalation.

With the new partnership the Total Addressable Market (TAM) of the combined services increases by approximately 30%, exceeding €630M, adding about €150M to the previous market size addressable by ISAB alone.

Expertise every step of the way

Actarmo Medical has an established client base and highly valued specialist expertise in formulation development, analytical testing under full GMP, MDR consultancy and consultancy for all aspects of inhaler delivery devices.

ISAB is highly specialized for its high-precision preclinical PK (pharmaco-kinetic) studies that analyze and assess the behaviour of inhaled compounds early in the development process, enabling higher prediction in outcomes in clinical trials.

The partnership will include co-selling and co-marketing of the combined offering.

ISAB’s CEO Manoush Masarrat: “I am very pleased with this collaboration and confident that few service providers in the field will be able to offer a comparative level of expertise. Our teams share the same values and commitment, whilst bringing together a hugely competitive range of capabilities. The joint customer projects have so far proven to be very successful, and this partnership will enrich both organizations and our customers.”.

Actarmo Medical’s CEO Thomas Weuthen: “Actarmo Medical and ISAB work in complementary areas of the drug development and the combined range of services will be very appealing to customers, simplifying their inhalation drug product development process. ISAB’s services do fill a gap we have seen several times within our projects, and we are happy to now work closely with ISAB. This collaboration brings us new customers which we did not address until now and I am really looking forward to this cooperation!”.